The stock of OvaScience Inc (NASDAQ:OVAS) is a huge mover today! About 172,960 shares traded hands. OvaScience Inc (NASDAQ:OVAS) has risen 29.01% since February 29, 2016 and is uptrending. It has outperformed by 16.79% the S&P500.
The move comes after 7 months positive chart setup for the $260.25M company. It was reported on Oct, 3 by Barchart.com. We have $10.27 PT which if reached, will make NASDAQ:OVAS worth $101.50M more.
Analysts await OvaScience Inc (NASDAQ:OVAS) to report earnings on November, 3. They expect $-0.62 EPS, up 6.06% or $0.04 from last year’s $-0.66 per share. After $-0.62 actual EPS reported by OvaScience Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
OvaScience Inc (NASDAQ:OVAS) Ratings Coverage
Out of 5 analysts covering OvaScience (NASDAQ:OVAS), 1 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 20% are positive. OvaScience has been the topic of 9 analyst reports since August 11, 2015 according to StockzIntelligence Inc. Credit Suisse initiated the shares of OVAS in a report on Thursday, January 21 with “Underperform” rating. Oppenheimer maintained OvaScience Inc (NASDAQ:OVAS) rating on Wednesday, October 21. Oppenheimer has “Outperform” rating and $16 price target. Oppenheimer maintained it with “Outperform” rating and $12.0 target price in Wednesday, September 30 report. As per Monday, November 9, the company rating was downgraded by Leerink Swann. Oppenheimer downgraded the stock to “Perform” rating in Monday, January 25 report. On Friday, August 14 the stock rating was maintained by Leerink Swann with “Outperform”. On Tuesday, September 29 the stock rating was downgraded by JMP Securities to “Mkt Perform”. Wedbush maintained OvaScience Inc (NASDAQ:OVAS) rating on Tuesday, August 11. Wedbush has “Outperform” rating and $46 price target.
According to Zacks Investment Research, “OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 3.37 in 2016 Q2. Its up 2.50, from 0.87 in 2016Q1. The ratio improved, as 7 funds sold all OvaScience Inc shares owned while 12 reduced positions. 17 funds bought stakes while 47 increased positions. They now own 51.93 million shares or 132.78% more from 22.31 million shares in 2016Q1.
The New Jersey-based Kcg has invested 0% in OvaScience Inc (NASDAQ:OVAS). Voya Inv Management Ltd Limited Liability Company, a Georgia-based fund reported 15,549 shares. Manufacturers Life Insurance The has 23,773 shares for 0% of their US portfolio. Barclays Public Ltd Company has 0% invested in the company for 552 shares. The Pennsylvania-based Brandywine Management Ltd Liability Corp has invested 0% in OvaScience Inc (NASDAQ:OVAS). Bbt Cap Management Limited holds 0.21% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 253,680 shares. Northern Cap Ltd Co has invested 0.07% of its portfolio in OvaScience Inc (NASDAQ:OVAS). Moreover, Teacher Retirement Sys Of Texas has 0% invested in OvaScience Inc (NASDAQ:OVAS) for 3,938 shares. Awm Investment Incorporated last reported 0.06% of its portfolio in the stock. Dimensional Fund L P reported 13,395 shares or 0% of all its holdings. Blackrock Advisors Lc accumulated 0% or 13,472 shares. Amici Cap Limited Liability owns 10,000 shares or 0.01% of their US portfolio. Mount Lucas Management Ltd Partnership reported 3,300 shares or 0% of all its holdings. Panagora Asset Mngmt holds 0% of its portfolio in OvaScience Inc (NASDAQ:OVAS) for 915 shares. Stoneridge Prtn Limited Liability Co accumulated 0.04% or 49,960 shares.
Insider Transactions: Since May 10, 2016, the stock had 10 insider purchases, and 0 sales for $1.76 million net activity. Dipp Michelle had bought 20,000 shares worth $157,200. ALDRICH RICHARD had bought 36,095 shares worth $250,395. 3,100 OvaScience Inc (NASDAQ:OVAS) shares with value of $22,847 were bought by CHAPMAN PAUL W.D..
OVAS Company Profile
OvaScience, Inc., incorporated on April 5, 2011, is a global fertility company. The Firm is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization (IVF) process to supplement the existing mitochondria.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.